- Report
- September 2023
- 120 Pages
Global
From €5754EUR$5,950USD£4,873GBP
- Report
- February 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,095GBP
- Report
- April 2024
- 472 Pages
Global
From €5415EUR$5,600USD£4,586GBP
- Report
- November 2023
- 138 Pages
Global
From €2417EUR$2,499USD£2,047GBP
- Report
- February 2024
- 171 Pages
Global
From €4739EUR$4,900USD£4,013GBP
- Report
- December 2022
- 142 Pages
Global
From €3411EUR$3,528USD£2,889GBP
€4013EUR$4,150USD£3,399GBP
- Report
- September 2018
- 112 Pages
Global
From €2659EUR$2,750USD£2,252GBP
- Report
- August 2023
- 99 Pages
Global
From €3500EUR$3,877USD£3,068GBP
The ADME Toxicology Testing market is a subset of the Drug Discovery market, which focuses on the development of new drugs. ADME stands for Absorption, Distribution, Metabolism, and Excretion, and Toxicology Testing is the process of assessing the safety of a drug. This testing is conducted to ensure that the drug is safe for human use and does not cause any adverse effects. The testing process involves the use of in vitro and in vivo models, as well as the use of biomarkers to measure the drug’s toxicity. The results of the testing are then used to determine the safety of the drug and its potential for use in clinical trials.
Some of the companies in the ADME Toxicology Testing market include Charles River Laboratories, Eurofins Scientific, WuXi AppTec, SGS, and Covance. Show Less Read more
